Reverse transcriptase with improved properties

GB2630305APending Publication Date: 2024-11-27THERMO FISHER SCI BALTICS UAB
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
GB2023007629
Authority / Receiving Office
GB · GB
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-27

Smart Images

  • Figure 00000001_0000
    Figure 00000001_0000
  • Figure 00000002_0000
    Figure 00000002_0000
  • Figure 00000003_0000
    Figure 00000003_0000
Patent Text Reader

Abstract

Reverse transcriptase enzymes comprising a modified Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase amino acid sequence, wherein said amino acid sequence comprises a mutation compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase, and said enzyme possesses increased inhibitor resistance compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase. The variants may be at positions 416 and / or 267 and / or 674 and / or 186 of SEQ ID NO.1. Specifically the variants may be I416Q, I416N, I416T or I416S; K267Q, K267N or K267S; N674D or N674E; T186A, T186V, T186I, T186L or T186M. The present invention also relates to compositions, reaction mixtures, and kits comprising the said reverse transcriptase enzymes, and methods for reverse transcription of RNA wherein the said reverse transcriptase enzymes are used to synthesize cDNA from RNA.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A reverse transcriptase enzyme comprising a modified Moloney Murine Leukaemia Virus reverse transcriptase amino acid sequence, wherein said amino acid sequence comprises a mutation at position 1416, and / or K267, and / or N674, and / or T186 compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase of SEQ ID NO: 1, wherein said enzyme possesses increased inhibitor resistance compared to said wild-type Moloney Murine Leukaemia Virus reverse transcriptase.

2. The reverse transcriptase enzyme according to claim 1, wherein said amino acid sequence has at least two mutations at positions selected from the group consisting of: 1416, K267, N674 and T186.

3. The reverse transcriptase enzyme according to claim 2, wherein the at least two mutations are at positions 1416 and K267.

4. The reverse transcriptase enzyme according to claim 2, wherein the at least two mutations are at positions N674 and K267.

5. The reverse transcriptase enzyme according to any of the preceding claims, wherein the amino acid sequence comprises at least one further mutation at one or more of the following amino acid positions:P51     H204    N249 D524    E562    K571 T330    N479    L603 M66    L139    D200 T306     F309 D583 M289 T287    H594E607 Q221 149 A502 D653 K658 P130 Q237 A307 Y344 Q430 D449 A644 N649 L671 E673 M39 Q91 W388 1179 L333 R390 Q374 E5 E69 E302 W313 L435 N454 D124 E2866. The reverse transcriptase enzyme according to any preceding claim comprising a mutation selected from the group consisting of I416Q, I416N, I416T, I416S.

7. The reverse transcriptase enzyme according to claim 6 comprising an I416T mutation (SEQ ID NO: 2).

8. The reverse transcriptase enzyme according to any preceding claim, comprising a mutation selected from the group consisting of K267Q, K267N, K267S.

9. The reverse transcriptase enzyme according to claim 8 comprising a K267Q mutation (SEQ ID NO: 3).

10. The reverse transcriptase enzyme according to any preceding claim comprising a mutation selected from the group consisting of N674D or N674E.

11. The reverse transcriptase enzyme according to claim 10 comprising a N674D mutation (SEQ ID NO: 4).

12. The reverse transcriptase enzyme according to any preceding claim, comprising a mutation at position K267 that is not K267T.

13. The reverse transcriptase enzyme according to any preceding ciaim, comprising a mutation at position T186 that is not T186C or T186D.

14. The reverse transcriptase enzyme according to ciaim 13 comprising a mutation selected from the group consisting of T186A, T186V, T186I, T186L, T186M.

15. The reverse transcriptase enzyme according to claim 14, comprising a T186A mutation (SEQIDNO:5).

16. The reverse transcriptase enzyme according to any preceding claim comprising an I416T mutation, a K267Q. mutation, a N674D mutation, and / or a T186A mutation.

17. The reverse transcriptase enzyme according to claim 16 comprising an I416T mutation, a K267Q mutation, and / or a N674D mutation.

18. The reverse transcriptase enzyme according to claim 16 comprising an I416T mutation and a K267Q. mutation (SEQ. ID NO: 6).

19. The reverse transcriptase enzyme according to any preceding claim, wherein said enzyme confers increased resistance to hemin, tannic acid, humic acid, and guanidine isothiocyanate.

20. A composition comprising the reverse transcriptase according to any of the preceding claims.

21. A reaction mixture comprising the reverse transcriptase according to any of claims 1 to 19,22. Use of the reverse transcriptase according to any of claims 1 to 19 for reverse transcription of RNA.

23. A kit comprising the reverse transcriptase according to any of ciaims 1 to 19.

24. A polynucleotide encoding the reverse transcriptase enzyme according to any of claims 1 to 19.

25. A polynucleotide according to claim 24, wherein the polynucleotide is codon-optimised for expression in a target host.

26. A plasmid comprising the polynucleotide of claim 24 or claim 25,27. A cell comprising the reverse transcriptase according to any one of claims 1-19, the polynucleotide according to claims 24 or 25, or the plasmid according to claim 26.

28. A method for reverse transcription of RNA, wherein the reverse transcriptase according to any one of claims 1-19 is used to synthesise cDNA from RNA in a sample.

29. The method of claim 28, wherein the sample is selected from the group consisting of a biological sample, environmental sample, food product sample.

30. The method of claim 29, wherein the biological sample, environmental sample, or food product sample is a processed sample or a purified sample.

31. The method of claim 30, wherein the biological sample, environmental sample, or food product sample is an unprocessed sample or an unpurified sample.

Citation Information

Patent Citations

  • Mutant reverse transcriptase and preparation method and application thereof

    CN111849938A

  • Novel reverse transcriptases for use in high temperature nucleic acid synthesis

    US20180010105A1

  • Reverse transcriptase variants for improved performance

    WO2022265965A1